MedPath

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

Recruiting
Conditions
Lung Cancer
Interventions
Genetic: comparative genomic hybridization
Genetic: gene expression microarray analysis
Genetic: proteomic profiling analysis
Other: biologic sample preservation procedure
Procedure: nasal brushing
Procedure: Blood draw
Procedure: Urine collection
Procedure: sputum sample
Procedure: fluorescence bronchoscopy with airway biopsy
Procedure: fine needle aspiration of the lung
Procedure: thoracentesis
Registration Number
NCT00898313
Lead Sponsor
Vanderbilt-Ingram Cancer Center
Brief Summary

RATIONALE: Using samples of blood, urine, sputum, and lung tissue from patients at high risk of cancer for laboratory studies may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is looking at molecular predictors of cancer in patients at high risk of lung cancer.

Detailed Description

OBJECTIVES:

* To use fixed lung tissue for histological evaluation and fresh tissue samples for molecular studies to study DNA, RNA, and protein abnormalities in lung preneoplastic and neoplastic lesions.

* To use proteomic techniques, including matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS), to develop a method of diagnosing and staging both pre-invasive and invasive lesions, using less invasive methods.

OUTLINE: Blood, urine, nasal cell, and sputum samples are collected. Lung tissue samples are also collected using fluorescence bronchoscopy and epithelial cell collection.

Samples are studied by genetic and proteomic analyses, including comparative genomic hybridization, expression microarray, and protein profiling.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
4000
Inclusion Criteria

-All adults referred to Vanderbilt Medical Center, Veterans Administration Medical Center, St. Thomas Hospital and Meharry Medical Center for evaluation of signs or symptoms of lung cancer.

Exclusion Criteria
  • Inability to provide informed consent
  • Minors
  • Pregnant women

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Sample Collectiongene expression microarray analysis-
Sample Collectionsputum sample-
Sample Collectionfine needle aspiration of the lung-
Sample Collectionthoracentesis-
Sample Collectionproteomic profiling analysis-
Sample Collectionbiologic sample preservation procedure-
Sample Collectionfluorescence bronchoscopy with airway biopsy-
Sample Collectioncomparative genomic hybridization-
Sample Collectionnasal brushing-
Sample CollectionBlood draw-
Sample CollectionUrine collection-
Primary Outcome Measures
NameTimeMethod
To quantitate the molecular changes during lung cancer developmentAfter collection of designated samples

As a part of the study nasal brushing specimens, sputum, blood, urine, and a small amount of other tissue will be collected during standard of care procedures (bronchial epithelial, trans-thoracic fine needle aspiration (FNA) and thoracentesis as part of patient work up.

Clinical diagnosis is the primary goal of the procedure. All the research specimens are collected after the primary goal of the procedure is met.

Secondary Outcome Measures
NameTimeMethod
Develop a method to diagnose and stage pre-invasive and invasive lesionsAfter collection of designated samples

Use of proteomic techniques in the laboratory to find a method of diagnosing lung tissue as benign or malignant rather than relying on invasive open-chest surgery for a diagnosis

Trial Locations

Locations (2)

Vanderbilt-Ingram Cancer Center

🇺🇸

Nashville, Tennessee, United States

Veterans Affairs Medical Center - Nashville

🇺🇸

Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath